6-methoxy-pyridine-2-carbonyl chloride | 1269418-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-methoxy-pyridine-2-carbonyl chloride
• 英文别名: 6-Methoxypicolinoyl chloride；6-methoxypyridine-2-carbonyl chloride
• CAS: 1269418-09-8
• 化学式: C₇H₆ClNO₂
• 分子量: 171.583
• InChiKey: NQDGFDNSIYDMJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-methoxy-pyridine-2-carbonyl chloride 在 sodium hydrogen sulfide 、 potassium hydroxide 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 2.0h， 生成 carbon monoxide;iron(2+);2-[6-[(4-methoxyphenyl)methoxy]pyridin-2-yl]ethanone;6-methoxypyridine-2-carbothioate
  参考文献：
  名称：

  Several New [Fe]Hydrogenase Model Complexes with a Single Fe Center Ligated to an Acylmethyl(hydroxymethyl)pyridine or Acylmethyl(hydroxy)pyridine Ligand

  摘要：

  We have developed two novel synthetic methods, by which two types of mononuclear Fe model complexes for the active site of [Fe]hydrogenase are successfully synthesized. The first type of 2-acylmethyl-6-hydroxymethylpyridine-containing complexes, [2-COCH2-6-HOCH2C5H3N]Fe(CO)(2)G (1, G = PhCO2; 2, PhCOS; 3, PhCS2; 4, 2-S-6-MeC5H3N), were prepared by a one-pot method involving reaction of 2-TsO-6-HOCH2C5H3N (Ts = 4-MeC6H4SO2) with Na2Fe(CO)(4) followed by treatment of the resulting Fe(0) intermediate [Na(2-CH2-(6)-HOCH2C5H3N)Fe(CO)(4)] (M1) with (PhCO2)(2), (PhCOS)(2), (PhCS2)(2), and (2-S-6-MeC5H3N)(2) in 4972% yields, respectively. The second type of 2-acylmethyl-6-hydroxypyridine-containing complexes, (2-COCH2-6-HOC5H3N)Fe(CO)(2)(2-SCO-6-RC5H3N) (9a, R = MeO; 9b, R = PhS), could be prepared via a multiple-step synthetic method. This method involves (i) treatment of 2-ClCO-6-RC5H3N (R = MeO, PhS) with NaSH followed by acidification with diluted HCl to give 2-HSCO-6-RC5H3N (5a, R = MeO; 5b, R = PhS); (ii) further treatment of 5a,b with KOH to afford 2-KSCO-6-RC5H3N (6a, R = MeO; 6b, R = PhS); (iii) treatment of 2-TsOCH2-6-PMBOC5H3N (PMB = 4-MeOC6H4CH2) with Na2Fe(CO)4 followed by treatment of the resulting Fe(0) intermediate [Na(2-CH2-6-PMBOC5H3N)Fe(CO)(4)] (M-2) with Br2 or I2 to produce (2-COCH2-6-PMBOC5H3N)Fe(CO)3X (7a, X = Br; 7b, X = I); (iv) further treatment of 7a,b with 6a,b to yield (2-COCH2-6-PMBOC5H3N)Fe(CO)(2)(2-S-6-RC5H3N) (8a, R = MeO; 8b, R = PhS); and (v) finally, removal of the PMB groups from 8a,b under the action of deprotecting reagent CF3CO2H/EtSH to give complexes 9a,b. All compounds 14 and 5a,b9a,b with the exception of 7b are new and have been characterized by elemental analysis, spectroscopy, and, particularly for 1, 4, and 7a9a, X-ray crystallography.

  DOI：

  10.1021/om5009296
• 作为产物：
  描述：

  6-甲氧基吡啶-2-甲酸 在 氯化亚砜 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 6-methoxy-pyridine-2-carbonyl chloride
  参考文献：
  名称：

  铑（III）催化的Picolinamides的氧化烯烃氧化反应：3-Alkenylpicolinamides的便捷合成

  摘要：

  已开发了铑（III）催化的吡啶甲酰胺衍生物的选择性烯烃化反应。该反应显示出高区域选择性，低催化剂负载量（0.5 mol％），高收率和良好的官能团耐受性，为合成3-链烯基吡啶甲酸酰胺提供了便利的策略。

  DOI：

  10.1002/adsc.201300895

文献信息

• [EN] PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE ET LEUR UTILISATION À TITRE DE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR5
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013087805A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R1, R2, R3, R4, Q have meanings given in the description.

  这项发明涉及公式(I)化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1、R2、R3、R4、Q在描述中有给定的含义。
• NOVEL COMPOUNDS
  申请人：HEIMANN Annekatrin

  公开号：US20130158042A1

  公开（公告）日：2013-06-20

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. R 1 , R 2 , R 3 , R 4 , Q have meanings given in the description.

  这项发明涉及公式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。R1，R2，R3，R4，Q在描述中给出了含义。
• 1, 2, 4-TRIAZOLONE DERIVATIVE
  申请人：Kuwada Takeshi

  公开号：US20130197217A1

  公开（公告）日：2013-08-01

  The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.

  本发明提供了一种1,2,4-三唑酮衍生物，其表示为式（1A），具有对精氨酸加压素1b受体的拮抗活性或其药用盐，并提供了包含该化合物或盐作为活性成分的药物组合物，特别是在诸如情绪障碍、焦虑障碍、精神分裂症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫相关疾病或脱发等疾病中展现良好药代动力学的治疗或预防剂。
• Indolinyl-Thiazole Based Inhibitors of Scavenger Receptor-BI (SR-BI)-Mediated Lipid Transport
  作者：Chris Dockendorff、Patrick W. Faloon、Miao Yu、Willmen Youngsaye、Marsha Penman、Thomas J. F. Nieland、Partha P. Nag、Timothy A. Lewis、Jun Pu、Melissa Bennion、Joseph Negri、Conor Paterson、Garrett Lam、Sivaraman Dandapani、José R. Perez、Benito Munoz、Michelle A. Palmer、Stuart L. Schreiber、Monty Krieger

  DOI：10.1021/ml500154q

  日期：2015.4.9

  SR-BI. ML278 is a plasma-stable, noncytotoxic probe that exhibits moderate metabolic stability, thus displaying improved properties for in vitro and in vivo studies. Strikingly, ML278 and previously described inhibitors of lipid transport share the property of increasing the binding of HDL to SR-BI, rather than blocking it, suggesting there may be similarities in their mechanisms of action.

  通过高通量筛选的美国国立卫生研究院分子图书馆小分子知识库（NIH MLSMR），鉴定了由吲哚基-噻唑类有效的一类由清除剂受体B类I型介导的细胞脂质摄取抑制剂（SR-BI） ），以测定从HDL颗粒摄取荧光脂质DiI的方法。这类化合物由ML278（17 – 11）代表，它很有效（平均IC 50= 6 nM）和通过SR-BI摄取脂质的可逆抑制剂。ML278是一种血浆稳定的，无细胞毒性的探针，具有中等的代谢稳定性，因此在体外和体内研究中显示出改进的特性。令人惊讶的是，ML278和先前描述的脂质转运抑制剂具有增加HDL与SR-BI结合而不是阻断它的特性，表明它们的作用机理可能相似。
• Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them
  申请人：SANOFI

  公开号：US20140330009A1

  公开（公告）日：2014-11-06

  The invention relates to substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines of formula (I), their use as medicament, and pharmaceutical preparations comprising them. The compounds of formula (I) act on the TASK-1 potassium channel. The compounds are particularly suitable for the treatment or prevention of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.

  这项发明涉及到式(I)的取代4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶类化合物，它们作为药物的用途，以及包含它们的药物制剂。式(I)的化合物作用于TASK-1钾通道。这些化合物特别适用于治疗或预防心房心律失常，例如心房颤动（AF）或心房扑动。